Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
for Atherosclerotic Cardiovascular Disease
139 locations incl. Daphne
Sponsor: Amgen
Sex: All·Age: 45 - 99
Code: NCT07037433·Phase 3·Recruiting